Literature DB >> 14966067

Multi-vessel coronary disease and percutaneous coronary intervention.

C Casey1, David P Faxon.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 14966067      PMCID： PMC1768119          DOI： 10.1136/hrt.2003.018986

Source DB:  PubMed          Journal:  Heart        ISSN： 1355-6037            Impact factor:   5.994


× No keyword cloud information.
  28 in total

1.  Long-term clinical outcome in the Bypass Angioplasty Revascularization Investigation Registry: comparison with the randomized trial. BARI Investigators.

Authors:  F Feit; M M Brooks; G Sopko; N M Keller; A Rosen; R Krone; P B Berger; R Shemin; M J Attubato; D O Williams; R Frye; K M Detre
Journal:  Circulation       Date:  2000-06-20       Impact factor: 29.690

2.  Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients.

Authors:  S Yusuf; P Sleight; J Pogue; J Bosch; R Davies; G Dagenais
Journal:  N Engl J Med       Date:  2000-01-20       Impact factor: 91.245

3.  Outcomes at 1 year and economic implications of platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting: results from a multicentre randomised trial. EPISTENT Investigators. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting.

Authors:  E J Topol; D B Mark; A M Lincoff; E Cohen; J Burton; N Kleiman; D Talley; S Sapp; J Booth; C F Cabot; K M Anderson; R M Califf
Journal:  Lancet       Date:  1999-12-11       Impact factor: 79.321

4.  Reduced coronary events in simvastatin-treated patients with coronary heart disease and diabetes or impaired fasting glucose levels: subgroup analyses in the Scandinavian Simvastatin Survival Study.

Authors:  S M Haffner; C M Alexander; T J Cook; S J Boccuzzi; T A Musliner; T R Pedersen; J Kjekshus; K Pyörälä
Journal:  Arch Intern Med       Date:  1999 Dec 13-27

5.  The effect of previous coronary-artery bypass surgery on the prognosis of patients with diabetes who have acute myocardial infarction. Bypass Angioplasty Revascularization Investigation Investigators.

Authors:  K M Detre; M S Lombardero; M M Brooks; R M Hardison; R Holubkov; G Sopko; R L Frye; B R Chaitman
Journal:  N Engl J Med       Date:  2000-04-06       Impact factor: 91.245

6.  Is a strategy of intended incomplete percutaneous transluminal coronary angioplasty revascularization acceptable in nondiabetic patients who are candidates for coronary artery bypass graft surgery? The Bypass Angioplasty Revascularization Investigation (BARI).

Authors:  M G Bourassa; K E Kip; A K Jacobs; R H Jones; G Sopko; A D Rosen; B L Sharaf; L Schwartz; B R Chaitman; E L Alderman; D R Holmes; G S Roubin; K M Detre; R L Frye
Journal:  J Am Coll Cardiol       Date:  1999-05       Impact factor: 24.094

7.  Low-molecular-weight heparins in non-ST-segment elevation ischemia: the ESSENCE trial. Efficacy and Safety of Subcutaneous Enoxaparin versus intravenous unfractionated heparin, in non-Q-wave Coronary Events.

Authors:  M Cohen; C Demers; E P Gurfinkel; A G Turpie; G J Fromell; S Goodman; A Langer; R M Califf; K A Fox; J Premmereur; F Bigonzi
Journal:  Am J Cardiol       Date:  1998-09-10       Impact factor: 2.778

8.  Seven-year outcome in the Bypass Angioplasty Revascularization Investigation (BARI) by treatment and diabetic status.

Authors: 
Journal:  J Am Coll Cardiol       Date:  2000-04       Impact factor: 24.094

9.  Eight-year mortality in the Emory Angioplasty versus Surgery Trial (EAST)

Authors:  S B King; A S Kosinski; R A Guyton; N J Lembo; W S Weintraub
Journal:  J Am Coll Cardiol       Date:  2000-04       Impact factor: 24.094

10.  Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes.

Authors: 
Journal:  N Engl J Med       Date:  1998-08-13       Impact factor: 91.245
View more
  3 in total

1.  Cardiogoniometry Compared to Fractional Flow Reserve at Identifying Physiologically Significant Coronary Stenosis: The CARDIOFLOW Study.

Authors:  Oliver I Brown; Andrew L Clark; Raj Chelliah; Benjamin J Davison; Adam N Mather; Michael S Cunnington; Joseph John; Albert Alahmar; Richard Oliver; Konstantinos Aznaouridis; Angela Hoye
Journal:  Cardiovasc Eng Technol       Date:  2018-04-12       Impact factor: 2.495

2.  The efficacy and safety of cangrelor in single vessel vs multivessel percutaneous coronary intervention: Insights from CHAMPION PHOENIX.

Authors:  Celina M Yong; Vandana Sundaram; Freddy Abnousi; Christoph B Olivier; Jaden Yang; Gregg W Stone; Philippe G Steg; C Michael Gibson; Christian W Hamm; Matthew J Price; Efthymios N Deliargyris; Jayne Prats; Harvey D White; Robert A Harrington; Deepak L Bhatt; Kenneth W Mahaffey
Journal:  Clin Cardiol       Date:  2019-06-29       Impact factor: 2.882

3.  Comparison of long-term clinical outcomes in multivessel coronary artery disease patients treated either with bioresoarbable polymer sirolimus-eluting stent or permanent polymer everolimus-eluting stent: 5-year results of the CENTURY II randomized clinical trial.

Authors:  Andrés Iñiguez; Bernard Chevalier; Gert Richardt; Antoinette Neylon; Victor A Jiménez; Ran Kornowski; Didier Carrie; Raul Moreno; Emanuele Barbato; Antoni Serra-Peñaranda; Vincenzo Guiducci; Mariano Valdés-Chávarri; Junji Yajima; William Wijns; Shigeru Saito
Journal:  Catheter Cardiovasc Interv       Date:  2019-04-29       Impact factor: 2.692
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.